about
When to start aripiprazole therapy in patients with bipolar maniaSleep disturbance in mental health problems and neurodegenerative diseasePsychometric properties of the self-report version of the Quick Inventory of Depressive Symptoms (QIDS-SR₁₆) questionnaire in patients with schizophreniaPhysical performance and disability in schizophrenia.The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial.Safety and tolerability of antipsychotic polypharmacy.Managing mental illness in Ghana: the state of commonly prescribed psychotropic medicines.Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth.H3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice.Asenapine effects in animal models of psychosis and cognitive function.Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study.Is seroquel developing an illicit reputation for misuse/abuse?Fewer classes of drugs for more and more psychiatric disorders.Evaluation of sleep profile in schizophrenia patients treated with extended-release paliperidone: an open-label prospective study in Southeast Asia.Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.Olanzapine Versus Risperidone in Children and Adolescents with Psychosis: A Meta-Analysis of Randomized Controlled Trials.Risperidone Provides Better Improvement of Sleep Disturbances Than Haloperidol Therapy in Schizophrenia Patients With Cannabis-Positive UrinalysisManagement of common adverse effects of antipsychotic medications
P2860
Q27014860-7C480909-2373-4370-B670-6A79E288DEEEQ28681847-E60AAFE9-55DD-4012-8C53-C3E7C90B161AQ34157106-23D32B4D-DCE1-4692-8D05-1E0E9BB13B6AQ34224072-A6822332-E361-4EF1-B9EF-B30C25FB1888Q35154166-512A4316-CC77-4697-913D-D544BBDF6BBDQ36062421-1786EC32-343F-4E1E-A577-11AEBA572F30Q36765757-A181CE40-E254-4483-B802-795298EA2985Q37061277-1D863E5C-55A7-4343-9A9F-4ACF76DB2309Q37273493-1E1D96DB-6743-4641-99B7-E57E13B30801Q37370296-5DA2B9AE-FC11-43F1-AA8F-02410ADDD4A1Q38997108-725C8467-88CB-4AE9-B94F-D48DFCED5400Q39872698-D9597D24-73D0-4AF6-A007-0D3BC0467E0BQ43251231-CB9B5B86-1FEB-4B58-B9A3-7B86D442D8EFQ46348298-12F468F6-F5B1-41B6-BDE9-4708EC11C1DAQ47160314-44210947-0693-43DF-B205-4EF88A177CEFQ47642665-1F3F949E-5D89-4445-8196-A92D0857BC74Q56526209-802D899F-1FB3-4C29-B03E-B527D428E900Q58760350-B8738241-5D62-49FF-9427-8C5128DA66A0
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Atypical antipsychotics: sleep, sedation, and efficacy
@ast
Atypical antipsychotics: sleep, sedation, and efficacy
@en
Atypical antipsychotics: sleep, sedation, and efficacy
@nl
type
label
Atypical antipsychotics: sleep, sedation, and efficacy
@ast
Atypical antipsychotics: sleep, sedation, and efficacy
@en
Atypical antipsychotics: sleep, sedation, and efficacy
@nl
prefLabel
Atypical antipsychotics: sleep, sedation, and efficacy
@ast
Atypical antipsychotics: sleep, sedation, and efficacy
@en
Atypical antipsychotics: sleep, sedation, and efficacy
@nl
P2860
P1476
Atypical antipsychotics: sleep, sedation, and efficacy
@en
P2093
Del D Miller
P2860
P433
P577
2004-01-01T00:00:00Z